title: Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets.
authors.affiliation: Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands.
authors.forename: Egbert F
authors.initials: EF
authors.lastname: Smit
authors.affiliation: Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands.
authors.forename: Paul
authors.initials: P
authors.lastname: Baas
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D059447:Cell Cycle Checkpoints / Q000187:drug effects / Q000276:immunology; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors / Q000276:immunology; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends*
chemical_list: D000911:Antibodies, Monoclonal; D018797:Cell Cycle Proteins